To study some aspects of Epstein-Barr virus (EBV) penetration into target cells, the effect of concanavalin A (ConA) and various saccharides on virus infectivity and cell susceptibility to EBV infection was examined. ConA treatment of the target cells, EBV, or EBV-cell complexes was found to inhibit virus antigen expression. Several control experiments with a-D-methyl-mannoside elution of ConA, removal of nonfused EBV particles from the cell surface by trypsin treatment, and addition of ConA at different times postinfection were performed to define the site of ConA action on EBV infection. ConA appeared to have a dual action: (i) it inhibited EBV binding to virus receptors, and (ii) it blocked the penetration of receptor-bound virus into target cells at a trypsin-sensitive stage, thus indicating that ConA prevented the fusion of viral envelope with the target cell membrane. A high sucrose concentration (0.25 M), known to inhibit cell membrane movements, was also found to block EBV penetration at a trypsinsensitive stage, thus suggesting the implication of cell membrane movements and underlying activities (or both) in viral envelope fusion. Lower concentrations of various monosaccharides (0.12 M) did not influence EBV infection. Under conditions of ConA treatment that did not influence EBV infectivity and target cells susceptibility, ConA was able to mediate virus binding to EBV receptornegative cell lines, but no virus antigens were expressed in these cells. These observations reinforced the idea that the mere attachment of EBV to lymphoid cells is not sufficient to lead to infection. In light of the present and previously published data, we postulate the existence of a specific cellular mechanism that allows the penetration of EBV into the target (B) lymphocyte.
To study some aspects of Epstein-Barr virus (EBV) penetration into target cells, the effect of concanavalin A (ConA) and various saccharides on virus infectivity and cell susceptibility to EBV infection was examined. ConA treatment of the target cells, EBV, or EBV-cell complexes was found to inhibit virus antigen expression. Several control experiments with a-D-methyl-mannoside elution of ConA, removal of nonfused EBV particles from the cell surface by trypsin treatment, and addition of ConA at different times postinfection were performed to define the site of ConA action on EBV infection. ConA appeared to have a dual action: (i) it inhibited EBV binding to virus receptors, and (ii) it blocked the penetration of receptor-bound virus into target cells at a trypsin-sensitive stage, thus indicating that ConA prevented the fusion of viral envelope with the target cell membrane. A high sucrose concentration (0.25 M), known to inhibit cell membrane movements, was also found to block EBV penetration at a trypsinsensitive stage, thus suggesting the implication of cell membrane movements and underlying activities (or both) in viral envelope fusion. Lower concentrations of various monosaccharides (0.12 M) did not influence EBV infection. Under conditions of ConA treatment that did not influence EBV infectivity and target cells susceptibility, ConA was able to mediate virus binding to EBV receptornegative cell lines, but no virus antigens were expressed in these cells. These observations reinforced the idea that the mere attachment of EBV to lymphoid cells is not sufficient to lead to infection. In light of the present and previously published data, we postulate the existence of a specific cellular mechanism that allows the penetration of EBV into the target (B) lymphocyte. (11, 25) , and its genome is associated with two human cancers: Burkitt's lymphoma (5) and nasopharyngeal carcinoma (7) . The main target cell for EBV infection is the B lymphocyte which bears specific EBV receptors (14, 18); this virus is also found in nasopharyngeal carcinoma cells which are of epithelial nature, however, and it is still unknown whether EBV is able to infect epithelial cells directly or indirectly by fusion of an EBV genome-carrying B-lymphoid cell and these cells (7) . The mode of entry of EBV into target cells seems to involve fusion of the viral envelope with the cell membrane, followed by release of the viral nucleocapsid into the cytoplasm (21, 32) . The cellular and viral factors that govern these processes are still unknown; they may prove to contribute largely to the narrow host range restriction of EBV, as indicated by the ability of this virus to bind to Molt-4 cells, but not to release its nucleocapsid into their cytoplasm (21) . The function of the different EBV envelope glycoproteins regarding receptor binding and envelope fusion has not been studied, mainly because of the lack of viral mutants with abnormal envelope functions and the lack of a model system for the study of EBV penetration. Model systems have been successfully developed for paramyxoviruses such as Sendai virus (SV) and have contributed to a clearer definition of the functions of such glycoproteins as hemagglutinin-neuraminidase and fusion factor (F1,2) of SV (13, 27, 37) . The simplest of these model systems consisted of the use of SV receptor-negative horse or cat erythrocytes and concanavalin A (ConA)-mediated binding of SV to these cells which thus became susceptible to SV-induced hemolysis; this indicated that the specific binding of viral hemagglutinin-neuraminidase to virus receptors is not necessary for the F1,2 protein to function in envelope fusion (37) .
Epstein-Barr virus (EBV) is a human herpesvirus that causes infectious mononucleosis
To initiate similar studies on the mechanism of BJA-B cells, respectively. These cells were then processed as for the formation of virus-cell complexes, and, when desired, they were eluted with MM as described above; then, the cells were cultured in RPMI-10 for 48 h. After each 48 h of culture, the cells were examined for EBV-induced early antigens (EA) or nuclear antigens (EBNA) as described below.
Effect of ConA on EBV penetration into target cells. The effect of ConA on B95-8 EBV penetration into BJA-B targets was examined in two different ways. In the first approach, the ConA-or sham-treated viruscell complexes were incubated for 2 h at 370C in RPMI, and virus particles that did not fuse with or penetrate the cells were removed by trypsin treatment. Trypsin (Difco Laboratories) was applied at a final concentration of 0.25% for 15 min at 370C. The cells were then washed with RPMI-10 and either immediately cultured or allowed to recover for 20 min at 370C in RPMI-10, eluted with MM at 4°C, and cultured for 48 h. After culture, the cells were examined for EBNA as described below.
In the second approach, all operations were conducted at 370C as follows. B95-8 EBV preparation was (21) or cultured for 48 h. After culture, the cells were examined for EBV-induced antigens as described below.
Detection of EBV antigens. After culture for 48 h under the usual conditions (as indicated above), the infected cells were harvested and washed in PBS by low-speed centrifugation. The cells were then smeared, air dried, and fixed with cold (-20°C) acetone-methanol (1:1). The cell smears were stained for EBNA by the two-step anticomplement immunofluorescence method (18) or stained for the EA by using anti-EA antibody-positive human serum and rabbit anti-human -y chain-specific conjugate as described previously (10) . washed with RPMI-10 and cultured for 48 h, whereas the samples with ovalbumin were cooled to 0 to 4°C in ice, washed with cold PBS, and treated with 0.25% trypsin at 40C for 30 min; they were then washed with RPMI-10 and cultured for 48 h. At the end of the culture period the cells were examined for the presence of EBNA as indicated above.
RESULTS
Effect of ConA on EBV infectivity. Before studying the outcome of ConA-mediated binding of EBV to receptor-negative cell lines, it was important to know the effect of various concentrations of ConA on the EBV replication cycle. Therefore, we first studied the effect of ConA on EBV infectivity by using the two EBV strains P3HR-1 and B95-8 and two different target cell lines Raji and BJA-B, respectively. The main properties of these two targets and the other cell lines used in these studies are shown in Table 1 (Fig. 1) . The showing that the virus was not irreversibly aliition of EBV infectivity by ConA tered by ConA (Table 2) . However, when the on virus concentration (Fig. 2) (Fig. 1) . When the ConA-treated cells Dated (control) B95-8 EBV.
were eluted with MM before incubation with ope-cell membrane fusion) before ConA of experiment were performed. In the first type, nent. The virus-cell complexes thus ob-trypsin treatment was used to remove from the I were treated with various ConA concen-cell surface virus particles that did not undergo ns in the cold and then warmed to 37°C and fusion with the cell membrane. In some samples, red under normal conditions. It was thus the ConA-treated virus-cell complexes were inthat ConA inhibited EBNA expression in cubated for 2 h at 37°C and subsequently treated centration-dependent manner (Fig. 3 ). Elu-with trypsin, treated with trypsin and eluted of ConA from the virus-cell complexes with MM (to remove any ConA bound to trypred the expression of EBNA (Table 3 ). This sin-resistant molecules, such as glycolipids), or sal of ConA-induced inhibition was ob-sham treated. In no case was EBNA detected. I either when the cold, ConA-treated com-However, in similarly treated samples in which s were immediately eluted with MM or complexes had not been treated with ConA, ated for 2 h at 37°C and subsequently EBNA was expressed normally ( (10 and 20 ,ug/ml) rendered the EBV receptor-negative cell lines (1301, P3HR-1, and B95-8) able to bind EBV to a degree that seems to be related to the ability of these cells to bind ConA (Table 1) is not sufficient to lead to virus infection. Therevirus infection and confirm the fore, some unknown cellular functions seem to ctin on virus penetration.
determine the fate of cell surface-bound EBV. v ConA concentrations on EBV EBNA induction in the presence of ovalbumin ve and receptor-positive cell lines. and various saccharides. The inhibition of early ,sults showed that ConA binds to EBV-target cell interactions by ConA described and the target cell and that low above could have resulted from the blocking of ations do not affect EBV antigen essential saccharide recognition markers by the decided to determine whether lectin. Therefore, different saccharides lN-aceconcentrations would mediate tyl-D-glucosamine, D-(+)-galactose, N-acetyl-Dto virus receptor-negative cell galactosamine, L-(-)-fucose, and MM] were as-)sitive cases, we were also inter-sayed for their ability to inhibit EBV penetration v whether this ConA-mediated at a final concentration of 0.12 M. Ovalbumin, be followed by EBV infection of which bears high mannose-type oligosacchawise are not susceptible to EBV rides that bind to ConA (2), was also assayed at a final concentration of 1.5 mg/ml. None of these treated various EBV-susceptible competitive inhibitors of oligosaccharide-meditible cell lines with low concen-ated interactions influenced EBNA expression inA (1, 10, and 20 FLg/ml) and (data not shown). In view of the nonspecific 3V to interact with these cells at action of saccharides at high concentrations on (Table 5 ).
The action of sucrose was reversible as shown by the full expression of EBNA when trypsin treatment, before the removal of sucrose, was omitted (Table 5) . DISCUSSION Previous studies in this laboratory have led to the identification of several lymphoid cell lines which bind EBV but do not allow expression of viral antigens (21, 28) . One of these cell lines, Molt-4, was studied by both immunofluorescence and electron microscopy; it was then found that the virus bound to the surface of Molt-4 cells, but neither viral antigens nor nucleocapsids could be detected in them (21) . These studies raised the possibility that, in these cells, EBV infection may be controlled at the level of virus penetration and prompted us to investigate the mechanism of penetration of this virus.
In the present studies, we wanted to evaluate the relative importance of cellular and viral functions that may contribute in determining the fate of cell surface-bound EBV: either penetration and antigen induction (in susceptible cells) or lack of penetration or infection or both (in Molt-4 and other resistant cells).
The results indicate that ConA inhibits EBV infectivity and protects the target cells against virus infection. This is in agreement with observations reported on other enveloped viruses (26, 34 (3, 29) . (ii) ConA, by virtue of its tetravalence, could crosslink and restrict the mobility of virus and cell surface glycoconjugates (9, 36) . This action of ConA, in turn, would inhibit envelope fusion which requires the mobility of membrane components (1, 16, 31).
We were not able to distinguish between these two possible mechanisms of ConA action by using a variety of inhibitors of oligosaccharidemediated interactions (4, 8, 33) ; these inhibitors (sugars and ovalbumin) were intended to compete with viral or cellular carbohydrate markers that might contribute to virus penetration, but did not show any effect. Therefore, if oligosaccharide-mediated interactions are actually involved in EBV penetration, they would rely on sugar configurations different from those assayed here; alternatively, the lack of effect of these inhibitors might indicate that the involved oligosaccharide-mediated interactions are irreversible.
In agreement with the second possible mecha-nism of ConA action, we found that high sucrose concentration (0.25 M) blocked EBV penetration, thus confirming the importance of the mobility of membrane components. Sucrose at high concentration is a strong inhibitor of cell membrane movements, as shown in the SVEhrlich ascites tumor cell system (17, 24) . In this system, sucrose does not prevent SV envelope fusion which is controlled exclusively by the viral fusion factor F1,2 whereas it prevents SVinduced cell-cell fusion which, in addition to the F1,2 glycoprotein, requires specific movements of the cell membrane and some function(s) of the cytoskeleton. Surprisingly, high sucrose concentration blocked EBV penetration at a trypsin-sensitive stage, indicating the absence of virus envelope fusion with the cell membrane. This suggests that EBV envelope fusion, unlike that of SV, depends on target cell membrane movements. However, our data do not show whether these membrane movements or the related mechanism of EBV penetration is induced upon EBV binding to specific virus receptors or represents a normal characteristic of EBV-susceptible cells. In any event, the need for specific virus-cell interactions to allow virus penetration is suggested by the inability of low ConA concentrations to render various resistant cell lines susceptible to EBV infection. At these concentrations, ConA was able to mediate EBV binding to receptor-negative cell lines and did not inhibit EBV infectivity in susceptible ones. It should be noted here that we had also chosen for these experiments EBV receptor-negative cell lines on the basis of their ability to support EBV antigen expression after the implantation into their membrane of EBV receptor-bearing Raji cell membrane fragments (35) . Therefore, it seems likely that the absence of EBV antigen induction in these resistant cells is due to the lack of virus penetration. The failure of ConA-mediated binding of EBV to lead to EBV antigen expression is in line with the observation that several EBV receptor-positive cell lines are not susceptible to EBV infection (28) ; it further consolidates the concept that factors other than the mere presence of virus receptors are responsible for the unusually narrow host range of EBV.
In conclusion, our results emphasize both the specificity and complexity of the events leading to EBV penetration into target cells. They constitute the first experimental evidence that EBV envelope fusion follows a different and more intricate pathway than that of the well-studied fusion of the SV envelope. This new pathway is not yet known, but it may rely partly or entirely on a cellular mechanism involving membrane movements that may be specifically triggered upon EBV binding to its specific receptors. It is also possible that these membrane movements or a related mechanism allowing EBV penetration represents, at least in part, membrane activities specific to the EBV-susceptible B-lymphoid cell. The understanding of the events governing EBV penetration may even lead to the identification of new properties of the B-lymphocyte membrane.
